General Information
Lemborexant is a dual orexin antagonist indicated for the treatment of sleep-onset and/or sleep maintenance insomnia. By blocking the activity of orexin, a neuropeptide responsible for regulating wakefulness, Lemborexant aids in facilitating sleep initiation and enhancing sleep maintenance. In contrast to traditional treatments that primarily target GABA and melatonin receptors to promote sleep drive, Lemborexant and other orexin antagonists work to counteract excessive wakefulness. This unique mechanism of action presents potential benefits such as a more favorable side effect profile and potentially greater effectiveness compared to conventional hypnotic medications.
About the API
Systematic name
(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide
Trade name(s)
Dayvigo
Technology
Synthetic
Molecular Formula
C22H20F2N4O2
Molecular Weight
410.4 g/mol
Therapeutic category
Neurology-Psychiatry
Available formulations
Oral Solid